Dr. Reddy's Laboratories, Incorporated

Other

Cancer Research Technology Limited

Agouron Pharmaceuticals, Inc.

Nereus Pharmaceuticals, Inc.

Pfizer Corporation

Latitude Pharmaceuticals, Inc.

Webb, Julie Ann

Sabino, Rafael Anthony

Chu, Jan-jon

Chen, Andrew Xian

Okumu, Franklin

Jan-Jon Chu

Andrew Xian Chen

Franklin W Okumu

Julie Ann Webb

Rafael Anthony Sabino

Bennett C Borer

Barbara Christine Potts

Ming Guo

Jia Liu

Naresh Nayyar

Zhen-Ping Wu

Yi Li

Mark Bryan Mitchell

Ramsharan Singh

Mohammad Saiful Islam

Jianmin Xu

Aparna Nadig Srirangam

Cheryl (Billstrom) Sifferlen

Natasha Reddinger

Bao Viet Mai

Bennett Chaplin Borer

This invention relates to clear one-phase liquid formulation vehicles comprising lecithin, MCT, bile salt and water.

Aqueous formulation for insoluble drugs

Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.

Parenteral compositions of celecoxib

Lyophilized formulations comprising Salinosporamide A or analogs thereof are provided. In some aspects, lyophilized formulations comprising Salinosporamide A or analogs thereof and bulking agents are provided. Also provided are methods of lyophilizing Salinosporamide A or analogs thereof. In some aspects, a solvent or co-solvent system is utilized. Also provided are methods of administering Salinosporamide A or analogs thereof to patients.

Lyophilized formulations of Salinosporamide A

The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-ce]indol-6-one

Growing community of inventors

Carlsbad, CA, United States of America

Jan-Jon Chu